<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapeutic use of ibutilide</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapeutic use of ibutilide</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Therapeutic use of ibutilide</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> is a class III antiarrhythmic drug available only for intravenous use for the termination of atrial arrhythmias. An oral form is not available because of extensive first-pass metabolism [<a href="#rid1">1</a>].</p><p>The physiology and pharmacology of <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> use and the side effects that can occur will be reviewed here. The pharmacokinetics of ibutilide, drug interactions, and the various clinical settings in which ibutilide might be used are discussed in detail separately.</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF ACTION</span></p><p class="headingAnchor" id="H106434424"><span class="h2">Cellular mechanisms</span><span class="headingEndMark"> — </span>Like other class III antiarrhythmic agents  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 1</a>), <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> prolongs repolarization in atrial and ventricular myocardium [<a href="#rid1">1,2</a>]. The class III drugs block IKr, the rapid component of the cardiac delayed rectifier potassium current. This results in prolonged repolarization, increased action potential duration, and lengthening of the refractory period [<a href="#rid1">1</a>]. Ibutilide increases the refractoriness of atrial and ventricular myocardium, the atrioventricular node, His-Purkinje system, and accessory pathway [<a href="#rid3">3</a>]. In addition, ibutilide activates a slow, delayed inward sodium current that occurs early during repolarization [<a href="#rid1">1,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/895.html" rel="external">"Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"</a> and <a class="local">'Major side effects'</a> below.)</p><p class="headingAnchor" id="H106434431"><span class="h2">Effects on the ECG</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> has two major effects on the electrocardiogram (ECG): it produces mild slowing of the sinus rate and, as with other class III antiarrhythmic drugs, prolongation of the QT interval. There is no effect on the PR interval or QRS duration.</p><p>The degree of QT prolongation associated with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> is related to the dose, the rate of infusion, and the serum concentration [<a href="#rid5">5</a>]. Prolongation of the QT interval provides the substrate for torsades de pointes (TdP), a polymorphic ventricular tachycardia. The QT interval returns to baseline within two to four hours after stopping the infusion. (See <a class="local">'Proarrhythmia'</a> below and <a class="local">'Discontinuing ibutilide infusion'</a> below.)</p><p class="headingAnchor" id="H106434349"><span class="h2">Mechanism of proarrhythmic effect</span><span class="headingEndMark"> — </span>Like other drugs that prolong the QT interval and cause torsades de pointes, <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> blocks IKr, the rapid component of the delayed rectifier potassium current that is responsible for phase 3 repolarization [<a href="#rid6">6</a>]. IKr results from a heteromeric complex formed by a tetrameric potassium channel encoded by the KCNH2 gene (formerly called HERG gene) in complex with an accessory subunit encoded by the MirP1 gene (KCNE2). (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Pathophysiology'</a>.)</p><p><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> exhibits "reverse use dependence", which is defined as an inverse correlation between the heart rate and QT interval. As a result, the QT interval decreases as the heart rate increases and lengthens as the heart rate slows. This explains why drug-induced polymorphic ventricular tachycardia (VT) is more commonly seen with bradycardia.</p><p>The effect of heart rate may be mediated by changes in the local extracellular potassium concentration [<a href="#rid7">7</a>]. Lower heart rates result in less potassium moving out of the cell during repolarization (before subsequent reuptake by the Na-K-ATPase pump), since there are fewer repolarizations. The associated reduction in extracellular potassium concentration enhances the degree of drug-induced inhibition of IKr, increasing the QT interval. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> has a half-life of 2 to 12 hours. It is extensively metabolized by the liver to eight metabolites. Only one metabolite exhibits antiarrhythmic activity, but its level is only approximately 10 percent of the parent drug level. As a result, this metabolite plays no role in the efficacy of ibutilide. Although almost 90 percent of the drug or its metabolites are detected in the urine, only 7 percent is excreted as the native, active drug.</p><p class="headingAnchor" id="H5117183"><span class="h1">CLINICAL USES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> is approved for the acute termination of atrial fibrillation and atrial flutter of recent onset. Since there is no oral preparation of ibutilide, it has no role in the long-term prevention of these arrhythmias. Ibutilide is not approved for the treatment of ventricular arrhythmias, and its efficacy for these arrhythmias is unknown.</p><p class="headingAnchor" id="H5117190"><span class="h2">Atrial fibrillation</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> is useful and effective for the pharmacologic cardioversion of recent-onset atrial fibrillation [<a href="#rid8">8</a>]. As with other antiarrhythmic drugs, the efficacy of ibutilide is greatest when the atrial fibrillation is of short duration  (<a class="graphic graphic_figure graphicRef62459" href="/z/d/graphic/62459.html" rel="external">figure 1</a>) [<a href="#rid9">9</a>]. </p><p>While it is of clear benefit in atrial fibrillation that has been present for seven days or less, the evidence is less robust but also suggests efficacy for atrial fibrillation of more than seven days duration. Most patients studied had arrhythmia for less than 90 days [<a href="#rid9">9-11</a>]. Similar efficacy has not been demonstrated with arrhythmia duration exceeding 90 days [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Specific antiarrhythmic drugs'</a>.)</p><p>The indications for pharmacologic cardioversion of atrial fibrillation and the settings in which <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> might be used are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p>In addition to the general use of <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> for cardioversion of atrial fibrillation, it has also been used in specific settings:</p><p class="bulletIndent1"><span class="glyph">●</span>As pretreatment before electrical cardioversion. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Preprocedural antiarrhythmic drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To convert atrial fibrillation to sinus rhythm in patients with Wolff-Parkinson-White syndrome. (See  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Atrial fibrillation with preexcitation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To convert atrial fibrillation to sinus rhythm after cardiac surgery or cardiac transplantation [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery"</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> also appears to be a safe and effective antiarrhythmic agent for cardioversion of recent-onset atrial fibrillation and flutter in elderly patients. In a study of 32 patients (mean age 76 years) with recent-onset atrial fibrillation (19 patients) or atrial flutter (13 patients), the overall rate of successful conversion was 59 percent with a mean conversion time was 33 minutes [<a href="#rid15">15</a>]. Ibutilide-induced lengthening of the QTc interval was 17±21 milliseconds.</p><p class="headingAnchor" id="H5117243"><span class="h2">Atrial flutter</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> is effective for the cardioversion of atrial flutter [<a href="#rid9">9-11,16</a>], including atrial flutter that occurs after cardiac surgery [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/1069.html" rel="external">"Restoration of sinus rhythm in atrial flutter"</a> and  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery"</a>.)</p><p class="headingAnchor" id="H5117310"><span class="h2">Ibutilide in children and in patients with congenital heart disease</span><span class="headingEndMark"> — </span>The safety and efficacy of <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> for cardioversion of atrial flutter and atrial fibrillation in children and in patients with congenital heart disease was reviewed in a report of 19 patients, age 6 months to 34 years (median 16 years) [<a href="#rid17">17</a>]. Ibutilide successfully restored sinus rhythm in 71 percent of arrhythmia episodes, with success during the first administration in 12 of 19 (63 percent). Fourteen episodes in six patients required electrical cardioversion after ibutilide failed. There were no episodes of symptomatic bradycardia, and only one episode each of polymorphic and monomorphic ventricular tachycardia. With careful monitoring, ibutilide can be effective for children and young patients with congenital heart disease for cardioversion of atrial arrhythmias.</p><p class="headingAnchor" id="H2797857781"><span class="h2">Chemical cardioversion of atrial fibrillation or flutter with ibutilide and other antiarrhythmic drugs</span><span class="headingEndMark"> — </span>Similar to <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>, intravenous <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a> has a short half-life, which makes it appealing for use in the acute conversion of atrial fibrillation. A randomized, prospective study comparing the combination of intravenous esmolol plus ibutilide with ibutilide monotherapy for conversion of recent-onset atrial fibrillation with a rapid ventricular rate showed improvement in the rate of conversion to sinus rhythm in the combined ibutilide/esmolol group (67 percent with the combination versus 46 percent for ibutilide monotherapy) [<a href="#rid18">18</a>]. The slower the ventricular rate at the time of ibutilide administration, the greater was the probability of conversion to sinus rhythm. In addition, there was a marked reduction in the incidence of immediate atrial fibrillation recurrence in the group receiving both esmolol and ibutilide. The ibutilide/esmolol combination was also associated with a lower risk of torsade de pointes.</p><p class="headingAnchor" id="H392856430"><span class="h3">Patients receiving amiodarone</span><span class="headingEndMark"> — </span>Combination therapy may be a useful cardioversion method for chronic atrial fibrillation or flutter for patients on <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> who are treated with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>. The efficacy and safety of cardioversion with combination amiodarone and ibutilide was evaluated in patients on long-term oral amiodarone and referred for elective cardioversion of atrial fibrillation (81 percent) or atrial flutter (19 percent) [<a href="#rid12">12</a>]. Patients, who were in the arrhythmia for a mean of 196 before cardioversion and were taking amiodarone for a mean of 153 days, were administered 2 mg intravenous ibutilide. Within 30 minutes of infusion, ibutilide converted 54 percent with atrial flutter and 39 percent with atrial fibrillation. One episode of torsade de pointes occurred although QT-interval prolongation after ibutilide was noted. Thirty-five (90 percent) of 39 patients who did not convert with ibutilide underwent successful electrical cardioversion. </p><p class="headingAnchor" id="H2458512898"><span class="h3">Patients receiving propafenone</span><span class="headingEndMark"> — </span>In a trial using combination therapy, concurrent administration of <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> plus <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> for pharmacological cardioversion of persistent atrial fibrillations was found safe and more effective than ibutilide alone [<a href="#rid19">19</a>]. Among 100 consecutive patients (66 men, mean age 65 years) with persistent atrial fibrillation (mean duration 99 days) who were admitted for elective pharmacological cardioversion and were randomly assigned to either intravenous ibutilide (1 mg plus an additional 1 mg, if required) or oral propafenone (600 mg) plus intravenous ibutilide, successful cardioversion occurred in 41 percent with ibutilide alone, compared with 71 percent with propafenone plus ibutilide. A comparable increase in the QTc interval was observed in both groups, but one case of sustained torsade de pointes, requiring electrical cardioversion, was observed in the propafenone plus ibutilide group.</p><p class="headingAnchor" id="H1511945826"><span class="h3">Patients undergoing catheter ablation for atrial fibrillation</span><span class="headingEndMark"> — </span>In patients with persistent atrial fibrillation undergoing catheter ablation, <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> administration was not shown to increase procedural efficacy and long-term freedom from atrial arrythmias [<a href="#rid20">20</a>]. In patients with persistent atrial fibrillation who are undergoing a catheter-based ablation, incorporation of electroanatomic mapping allows for the detection and targeting of complex fractionated atrial electrograms (CFAEs). Since ibutilide reduces CFAEs, it was hypothesized that ibutilide administration prior to CFAE ablation would identify sites critical for persistent atrial fibrillation maintenance, allowing for improved procedural efficacy and long-term freedom from atrial arrhythmias. In the MAGIC-AF trial, 200 patients undergoing a first-ever persistent atrial fibrillation catheter ablation procedure were randomly assigned to 0.25 mg of intravenous ibutilide or <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> placebo upon completion of pulmonary vein isolation. CFAE sites were then targeted with ablation. The study found that despite a reduction in CFAE area and greater atrial fibrillation termination during CFAE ablation, procedure efficacy was not statistically higher when CFAE ablation was guided by ibutilide administration versus placebo (56 versus 49 percent) [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/95704.html" rel="external">"Catheter ablation for the treatment of atrial fibrillation: Technical considerations for non-electrophysiologists"</a>.)</p><p class="headingAnchor" id="H16281208"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H16281136"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The recommended dose of <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> varies with patient size:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients weighing <strong>less than 60 kg</strong>, the dose is 0.01 mg/kg infused over 10 minutes. If the arrhythmia does not terminate within 10 minutes after the end of the infusion, a second bolus (same dose over 10 minutes) may be given.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients weighing <strong>more than 60 kg</strong>, the dose is 1 mg over 10 minutes. Again, if the arrhythmia does not terminate within 10 minutes after the end of the infusion, a second bolus of 1 mg over 10 minutes may be given.</p><p></p><p class="headingAnchor" id="H16281169"><span class="h2">Role of magnesium</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a> enhances the ability of intravenous <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> to successfully convert atrial fibrillation or flutter, and it can attenuate the QT interval prolongation associated with ibutilide therapy. Two cohort studies have shown that the concurrent administration of magnesium (doses of four to five grams administered intravenously) with ibutilide is associated with a greater chance of successful chemical conversion [<a href="#rid21">21,22</a>]. One of the two studies also reported a significantly lower rate of polymorphic ventricular tachycardia in patients who received the magnesium/ibutilide combination compared with patients who received only ibutilide [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H6"><span class="h1">MAJOR SIDE EFFECTS</span><span class="headingEndMark"> — </span>Side effects with the use of <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> are infrequent and typically transient. In one report, the only noncardiac side effects that occurred more frequently than with placebo were nausea (1.9 percent), headache (3.6 percent), and renal failure (0.3 percent) [<a href="#rid9">9</a>]. The most serious side effects are those involving the cardiovascular system. As a result, ibutilide should not be used in patients with severe structural cardiac disease, prolonged QT interval, or underlying sinus node disease. Additional information about potential drug interactions can be found using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H7"><span class="h2">Proarrhythmia</span><span class="headingEndMark"> — </span>Proarrhythmia, particularly nonsustained or sustained polymorphic (torsades de pointes) or monomorphic ventricular tachycardia (VT), is the most important toxic reaction. Because of the risk of ventricular tachycardia, particularly torsades de pointes, patients treated with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> should be observed with continuous ECG monitoring for at least four hours after the infusion is finished and longer if needed until the QTc interval has returned to baseline. </p><p>In several large series, polymorphic VT was seen in between four and eight percent of patients [<a href="#rid10">10,11,16,23</a>]. Sustained episodes requiring cardioversion were seen in approximately two percent of patients. In addition to polymorphic VT, nonsustained monomorphic VT occurred in three to four percent of patients [<a href="#rid10">10,11</a>]. The majority of episodes of sustained polymorphic VT occurred within ten minutes of the first dose (before the second dose would be given, if necessary).</p><p>Torsades de pointes may be more common in women, occurring in six percent of women in one series (versus three percent of men) [<a href="#rid23">23</a>]. In addition, the risk was increased in patients with heart failure (eleven percent versus four percent in those without heart failure) [<a href="#rid16">16</a>].</p><p>Class IC antiarrhythmic drugs, which slow conduction by blocking sodium channels, also have the potential for proarrhythmia. However, since class IC drugs do not cause QT prolongation, it has also been suggested these drugs can be used safely with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>. In two reports including a total of 175 patients with atrial fibrillation or atrial flutter, 150 were treated with <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> and 25 were treated with <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> [<a href="#rid24">24,25</a>]. All were treated with ibutilide up to 2 mg, which was successful in restoring sinus rhythm in 62 percent. Only two patients developed nonsustained polymorphic VT with one developing sustained polymorphic VT (two percent of patients), a rate consistent with that seen in patients not taking a class IC antiarrhythmic drug.</p><p>The potential for polymorphic VT is increased in patients who are being treated with another drug that prolongs the QT interval. However, the risk of proarrhythmia does not appear to be increased when <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> is given with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Other cardiac toxicities</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> has been associated with a number of cardiac side effects other than proarrhythmia [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension – 2 percent. Usually the degree of hypotension is mild and responds to fluid resuscitation.</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus tachycardia or supraventricular tachycardia – 2.7 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia – 1.2 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>Atrioventricular block – 1.5 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>Bundle branch block – 1.9 percent.</p><p></p><p>All of the above arrhythmias and conduction changes have been reported transient with minimal or no associated symptoms.</p><p class="headingAnchor" id="H10"><span class="h2">Hemodynamic effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> produces no clinically significant changes in left ventricular function or hemodynamics, including mean pulmonary artery pressure or pulmonary capillary wedge pressure, even in patients with reduced left ventricular ejection fraction [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H5117694"><span class="h2">Discontinuing ibutilide infusion</span><span class="headingEndMark"> — </span>In most patients who respond to <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>, arrhythmia termination is seen within 40 to 60 minutes after beginning the infusion (mean 27 to 33 minutes in two studies) [<a href="#rid11">11,16</a>]. The infusion should be stopped for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>The presenting arrhythmia is terminated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient develops ventricular tachycardia (sustained or nonsustained).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient develops marked prolongation of the QT interval (to a corrected QT interval &gt;500 msec with narrow QRS, or corrected QT &gt;550 msec in patients with bundle branch block).</p><p></p><p class="headingAnchor" id="H3709897757"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H92369783"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism and pharmacokinetics </strong>– <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a>, a class III antiarrhythmic drug, blocks IKr, the rapid component of the cardiac delayed rectifier potassium current. This results in prolonged repolarization, increased action potential duration, and lengthening of the refractory period. (See <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects on electrocardiogram </strong>– <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> has two major effects on the electrocardiogram (ECG): it produces mild slowing of the sinus rate and, as with other class III antiarrhythmic drugs, prolongation of the QT interval. There is no effect on the PR interval or QRS duration. Prolongation of the QT interval provides the substrate for torsades de pointes (TdP), a polymorphic ventricular tachycardia. (See <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical uses </strong>– <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">Ibutilide</a> is approved for the acute termination of atrial fibrillation and atrial flutter and is most useful and effective for the pharmacologic cardioversion of atrial fibrillation less than or equal to seven days duration. (See <a class="local">'Atrial fibrillation'</a> above and <a class="local">'Atrial flutter'</a> above and  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Specific antiarrhythmic drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects </strong>– Proarrhythmia, particularly nonsustained or sustained polymorphic ventricular tachycardia (VT) (torsades de pointes) or monomorphic VT, is the most important toxicity associated with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a>. Because of the risk of VT, particularly torsades de pointes, patients treated with ibutilide should be observed with continuous ECG monitoring for at least four hours after the infusion is finished, or until the QTc interval has returned to baseline. (See <a class="local">'Proarrhythmia'</a> above.)</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> infusion should be stopped for the following reasons (see <a class="local">'Discontinuing ibutilide infusion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presenting arrhythmia is terminated.</p><p class="bulletIndent2"><span class="glyph">•</span>The patient develops VT (sustained or nonsustained).</p><p class="bulletIndent2"><span class="glyph">•</span>The patient develops marked prolongation of the QT interval.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Murray KT. Ibutilide. Circulation 1998; 97:493.</a></li><li><a class="nounderline abstract_t">Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992; 222:93.</a></li><li><a class="nounderline abstract_t">Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001; 104:1933.</a></li><li><a class="nounderline abstract_t">Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99.</a></li><li><a class="nounderline abstract_t">Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993; 22:540.</a></li><li><a class="nounderline abstract_t">Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995; 91:1799.</a></li><li><a class="nounderline abstract_t">Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93:407.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li><li><a class="nounderline abstract_t">Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.</a></li><li><a class="nounderline abstract_t">Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28:130.</a></li><li><a class="nounderline abstract_t">Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998; 136:632.</a></li><li><a class="nounderline abstract_t">Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001; 103:253.</a></li><li><a class="nounderline abstract_t">VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100:369.</a></li><li><a class="nounderline abstract_t">Tallaj JA, Franco V, Rayburn BK, et al. Safety and efficacy of ibutilide in heart transplant recipients. J Heart Lung Transplant 2009; 28:505.</a></li><li><a class="nounderline abstract_t">Gowda RM, Khan IA, Punukollu G, et al. Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly. Am J Ther 2004; 11:95.</a></li><li><a class="nounderline abstract_t">Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.</a></li><li><a class="nounderline abstract_t">Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol 2007; 30:1003.</a></li><li><a class="nounderline abstract_t">Fragakis N, Bikias A, Delithanasis I, et al. Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate. Europace 2009; 11:70.</a></li><li><a class="nounderline abstract_t">Korantzopoulos P, Kolettis TM, Papathanasiou A, et al. Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. Heart 2006; 92:631.</a></li><li><a class="nounderline abstract_t">Singh SM, d'Avila A, Kim YH, et al. The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study). Eur Heart J 2016; 37:1614.</a></li><li><a class="nounderline abstract_t">Tercius AJ, Kluger J, Coleman CI, White CM. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol 2007; 30:1331.</a></li><li><a class="nounderline abstract_t">Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.</a></li><li><a class="nounderline abstract_t">Gowda RM, Khan IA, Punukollu G, et al. Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol 2004; 95:219.</a></li><li><a class="nounderline abstract_t">Chiladakis JA, Kalogeropoulos A, Patsouras N, Manolis AS. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol 2004; 44:859.</a></li><li><a class="nounderline abstract_t">Hongo RH, Themistoclakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004; 44:864.</a></li><li class="breakAll">http://www.bionichepharmausa.com/pdf/Ibutilide_Fumarate_PI.pdf.</li><li><a class="nounderline abstract_t">Stambler BS, Beckman KJ, Kadish AH, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997; 80:458.</a></li></ol></div><div id="topicVersionRevision">Topic 924 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490245" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ibutilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361444" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602497" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Electrophysiological effects of ibutilide in patients with accessory pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320693" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7505355" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7882490" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565156" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10078083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752805" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778066" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208685" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421596" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416781" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and efficacy of ibutilide in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999360" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840852" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17669084" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The safety and efficacy of ibutilide in children and in patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987127" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159973" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26850076" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976094" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20723644" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15193823" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Female preponderance in ibutilide-induced torsade de pointes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312872" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312873" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312873" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285658" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
